Category | Characteristic |
---|---|
General aspects | Type(s) of neoplasm(s) |
Year in which the trial was started♦ | |
Year in which the trial was completed♦ | |
Study duration∟ | |
Year in which the main results were published* | |
Journal in which the main results were published* | |
Impact factor of journal in which the main results were published*° | |
Digital object identifier of consulted publication(s) | |
Trial registry identifier(s) | |
Availability of protocol | |
Design elements | Clinical phaseâ–² |
Use of randomization | |
Use of blindingâ—Š | |
Number of study arms | |
Intervention(s) | |
Type of intervention(s) (e.g. pharmacotherapy, surgery, radiotherapy, etc.) | |
Comparator(s) | |
Type of comparator(s) (active or placebo; standard of care or not)∩ | |
Primary endpoint(s)/outcome measure(s) | |
Secondary endpoint(s)/outcome measure(s) | |
Organizational facets | Number of participants†|
Site-level setting (monocentric or multicentric)∆ | |
Country-level setting (national or international)â– | |
Countries in which the trial took place | |
Legal sponsorship⃞ | |
Funding source (commercial or non-commercial/academic)± |